Nexalin Technology Inc (NXL) Stock Price, Quote & News

Company Profile

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health epidemic in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic br...

Industry: Medical Devices

Sector: Healthcare

Phone: 832 260 0222

Website: www.nexalin.com

Address:

1776 Yorktown, Suite 550, Houston, United States

Stock_Catcher Sep. 10 at 11:54 AM

$NXL thin

0 · Reply

Dante_s_Inferno Sep. 8 at 2:09 PM

$NXL is this legal? lol

0 · Reply

watchat Sep. 4 at 2:12 PM

$NXL I’m honestly f**king p*ssed off with Nexalin. I invested because I actually believed in this company and its vision. But holy sh*t, their words and actions just don’t match. They said a reverse split wasn’t planned, and then they went ahead with a 1-for-30 reverse split anyway. The stock opened around $7.50 after the split, and now it’s already heading toward $4.50 because of the continued dilution. And now we’re seeing the registration of up to 5.75 million shares? Seriously, what the f*ck is going on with this company? 🤮

0 · Reply

PAULSTOCK57 Sep. 4 at 1:44 PM

$NXL now we are sure we will touch 1$ ❤️

1 · Reply

Dante_s_Inferno Sep. 2 at 7:08 PM

$NXL rsi 20 lol

0 · Reply

Dante_s_Inferno Sep. 1 at 1:49 PM

$NXL drop a news f*uckin pos

0 · Reply

TwongStocks Aug. 31 at 8:18 PM

Today's reverse split results. Tracked 10 reverse splits today. 4 of 10 closed green. Part 2 of 2: $NXL 1 for 30 Previous close $0.25, $7.50 split-adjusted Today's high $7.69 Today's close $7.23 🔴Down 3.60% $OMH 1 for 50 Previous close $0.07, $3.50 split-adjusted Today's high $3.97 (premarket) Today's close $3.24 🔴Down 7.43% $TPET 1 for 9 Previous close $0.2091, $1.8819 split-adjusted Today's high $1.98 Today's close $1.84 🔴Down 2.23% $VBIO 1 for 25 Previous close $0.1209, $3.0225 split-adjusted Today's high $3.87 Today's close $3.57 🟢Up 18.11% $VEEA 1 for 20 Previous close $0.1031, $2.062 split-adjusted Today's high $2.05 (premarket) Today's close $1.80 🔴Down 12.71%

0 · Reply

TwongStocks Aug. 31 at 11:25 AM

$NXL $OMH $VBIO $VEEA $TPET are among the several stocks with reverse split today. Every stock doing a RS will resume trading at 9:00am ET this morning.

0 · Reply

PSM_EmpowerTrading Aug. 31 at 3:24 AM

🌅 Watchlist part 2 ✅ $WETO low 7 support, above 7.20, potential to 8/8.70 🔄 $VBIO 1/25 reverse split (RS), new price ~3 🔄 $OMH 1/50 RS, new price ~3.50 🔄 $NXL 1/30 RS, new price ~7.50 🔄 $GCTK 1/15 RS, new price ~4.23 ✅ Ideal long entry near current support 🎯 Ideal stop loss below current support 🚨 Avoid chasing longs into strength near resistance 🎯🎯 Goal is GREEN 🤑🤑 not GREED 🥵🥵

0 · Reply

topstockalerts Aug. 29 at 1:51 AM

$NXL this is one of those setups you don’t want to ignore

0 · Reply

Nexalin Technology registers to sell 5.75M shares of common stock for holders

Sep 3, 2026, 8:30 AM EDT - 10 days ago

Nexalin Technology Announces New Secondary Analysis of Previously Published Clinical Trial Data Reveals Previously Unreported Improvements in Memory, Comprehension and Language Function in Alzheimer's Patients; ADAS-Cog Subscale Analysis to Guide Design of Planned U.S. Alzheimer's Pilot Study

Sep 3, 2026, 8:00 AM EDT - 10 days ago

Nexalin Technology Registration statement: Registration filing

2026-08-31T13:50:07.000Z - 13 days ago

Nexalin Technology Inc trading resumes

2026-08-31T13:45:18.000Z - 13 days ago

Nexalin Technology Inc trading halted, volatility trading pause

2026-08-28T23:55:24.000Z - 15 days ago

Nexalin Technology Inc trading halted, news pending

2026-08-27T11:30:38.000Z - 17 days ago

Nexalin Technology announces 1-for-30 reverse stock split

Aug 27, 2026, 7:25 AM EDT - 17 days ago

Nexalin Technology Announces Reverse Stock Split

Aug 12, 2026, 7:00 AM EDT - 4 weeks ago

Nexalin Technology Quarterly report: Q2 2026

Jul 10, 2026, 8:00 AM EDT - 2 months ago

Nexalin Technology Proxy statement: Proxy filing

Jun 29, 2026, 8:00 AM EDT - 2 months ago

Nexalin Technology Proxy statement: Proxy filing

2026-06-23T15:25:14.000Z - 2 months ago

Nexalin Technology investigator wins award for neurostimulation research

Jun 23, 2026, 8:30 AM EDT - 2 months ago

Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company's Proprietary DIFS™ Platform

Jun 16, 2026, 9:15 AM EDT - 2 months ago

Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life

2026-06-10T13:32:50.000Z - 3 months ago

Nexalin Technology completes neurostimulation protocol trial

Jun 10, 2026, 9:15 AM EDT - 3 months ago

Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan.

Jun 8, 2026, 6:56 AM EDT - 3 months ago

Nexalin Technology Registration statement

Jun 8, 2026, 6:56 AM EDT - 3 months ago

Nexalin Technology Quarterly report

2026-06-04T14:08:10.000Z - 3 months ago

Nexalin Technology announces issuance of new U.S. patent

Jun 4, 2026, 10:00 AM EDT - 3 months ago

Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia

May 21, 2026, 8:30 AM EDT - 3 months ago

Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury

May 19, 2026, 8:30 AM EDT - 3 months ago

Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial

May 8, 2026, 8:00 AM EDT - 4 months ago

Nexalin Technology Quarterly report: Q1 2026

Apr 28, 2026, 9:15 AM EDT - 4 months ago

Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia

2026-04-22T14:03:36.000Z - 4 months ago

Nexalin Technology enters agreements to advance HALO Clarity trial

Apr 22, 2026, 9:35 AM EDT - 4 months ago

Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment

2026-04-15T14:21:51.000Z - 5 months ago

Nexalin Technology advances FDA Alzheimer’s strategy

Apr 15, 2026, 10:00 AM EDT - 5 months ago

Nexalin Advances FDA Alzheimer's Strategy Following Landmark Leadership Meetings in the U.S. and China

Apr 14, 2026, 8:30 AM EDT - 5 months ago

Join Nexalin's Exclusive Live Investor Webinar and Q&A Session on April 21

Apr 9, 2026, 7:47 AM EDT - 5 months ago

Nexalin Announces Peer-Reviewed Study Showing the Company's DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents

2026-04-07T13:31:54.000Z - 5 months ago

Nexalin Technology price target lowered to $2 from $4 at Maxim

Mar 25, 2026, 8:00 AM EDT - 5 months ago

Nexalin Technology Annual report: Q4 2025

Mar 1, 2026, 7:00 AM EST - 6 months ago

Nexalin Technology Slides: Investor presentation

2026-02-24T13:34:50.000Z - 6 months ago

Nexalin announces continued advancement toward trial evaluating HALO Clarity

2026-02-24T13:29:27.000Z - 6 months ago

Nexalin announces continued advancement toward trial evaluating HALO Clarity

Feb 24, 2026, 8:07 AM EST - 6 months ago

Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market

2026-02-23T13:33:27.000Z - 6 months ago

Nexalin ‘commended’ recent Congressional initiative on neurostim research

Feb 23, 2026, 8:18 AM EST - 6 months ago

Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders

2026-02-05T13:46:39.000Z - 7 months ago

Nexalin Technology launches AI-designed virtual clinic platform NeuroCare

Feb 5, 2026, 8:37 AM EST - 7 months ago

Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer's, Mood Disorders, TBI & PTSD Care

2026-02-02T13:56:38.000Z - 7 months ago

Nexalin Technology highlights research validating neurostimulation technology

Feb 2, 2026, 8:45 AM EST - 7 months ago

Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation

2026-01-14T14:05:14.000Z - 8 months ago

Nexalin Technology announces publication of peer-reviewed study on DIFS

Jan 14, 2026, 9:00 AM EST - 8 months ago

Published Peer-Reviewed Study Demonstrates Nexalin's DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD

2025-12-03T13:05:47.000Z - 9 months ago

Nexalin Technology completes FDA Q-sub meeting for Gen-2 SYNC neurostimulation

Dec 3, 2025, 8:00 AM EST - 9 months ago

Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer's Disease Program

Dec 2, 2025, 8:00 AM EST - 9 months ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on December 4

2025-11-18T14:42:34.000Z - 9 months ago

Nexalin announces results for 15 mA neurostimulation device

Nov 18, 2025, 9:00 AM EST - 9 months ago

Nexalin's 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity

Nov 14, 2025, 7:00 AM EST - 10 months ago

Nexalin Technology Quarterly report: Q3 2025

2025-11-13T14:21:40.000Z - 10 months ago

Nexalin Technology appoints Carmi Masha as exclusive distributor in Israel

Nov 13, 2025, 9:15 AM EST - 10 months ago

Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel

Nov 5, 2025, 8:30 AM EST - 10 months ago

Nexalin Technology's Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer's Disease and Dementia

Oct 30, 2025, 8:30 AM EDT - 10 months ago

Nexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel

Oct 21, 2025, 9:00 AM EDT - 10 months ago

Nexalin's DIFS™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer's and Dementia Across Three Peer-Reviewed Studies

Oct 13, 2025, 8:30 AM EDT - 11 months ago

Nexalin Technology Expands Scientific Advisory Board with Appointment of Dr. Robert Rothstein to Support Alzheimer's and Traumatic Brain Injury Programs

Oct 10, 2025, 8:00 AM EDT - 11 months ago

Nexalin Technology Announces Attendance at the 2025 Maxim Growth Summit

Oct 8, 2025, 8:30 AM EDT - 11 months ago

Nexalin Technology Announces Additional Positive Clinical Results in Alzheimer's Disease with Gen-2 SYNC Neurostimulation Device

Sep 25, 2025, 8:30 AM EDT - 11 months ago

Nexalin Technology Announces Issuance of U.S. Patent Covering HALO™ Clarity Device Featuring DIFS™ Technology

Aug 25, 2025, 9:00 AM EDT - 1 year ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on September 9

Aug 6, 2025, 8:00 AM EDT - 1 year ago

Nexalin Technology Quarterly report: Q2 2025

Aug 1, 2025, 8:30 AM EDT - 1 year ago

Nexalin Technology Appoints Highly Experienced Financial Leader Justin Van Fleet as CFO to Support Nexalin's Next Phase of Growth and Strategic Initiatives

Jun 17, 2025, 8:00 AM EDT - 1 year ago

Nexalin Technology Proxy statement: Proxy filing

May 28, 2025, 10:00 AM EDT - 1 year ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on June 3

May 13, 2025, 8:30 AM EDT - 1 year ago

Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer's Program Amid Encouraging Data

May 13, 2025, 8:00 AM EDT - 1 year ago

Nexalin Technology Quarterly report: Q1 2025

May 6, 2025, 2:40 PM EDT - 1 year ago

Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering

May 5, 2025, 8:20 AM EDT - 1 year ago

Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock

May 1, 2025, 10:30 AM EDT - 1 year ago

Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback

Apr 24, 2025, 9:00 AM EDT - 1 year ago

Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia

Apr 23, 2025, 9:15 AM EDT - 1 year ago

Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Nexalin Technology Registration statement: Registration filing

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices

Apr 14, 2025, 12:30 PM EDT - 1 year ago

Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders

Apr 2, 2025, 8:30 AM EDT - 1 year ago

Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial

Mar 26, 2025, 8:30 AM EDT - 1 year ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on April 3

Mar 14, 2025, 8:00 AM EDT - 1 year ago

Nexalin Technology Annual report: Q4 2024

Mar 3, 2025, 8:30 AM EST - 1 year ago

Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders

Feb 28, 2025, 8:30 AM EST - 1 year ago

Nexalin Technology Announces Initiation of Patient Recruitment for UCSD's TBI & PTSD Clinical Study Following IRB Approval

Feb 26, 2025, 8:30 AM EST - 1 year ago

Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board

Feb 18, 2025, 8:30 AM EST - 1 year ago

Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment

Feb 10, 2025, 9:00 AM EST - 1 year ago

Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition

Feb 3, 2025, 8:30 AM EST - 1 year ago

Nexalin's Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study

Jan 30, 2025, 7:00 AM EST - 1 year ago

Nexalin Technology Registration statement: Registration filing

Jan 23, 2025, 11:00 AM EST - 1 year ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session, Today, January 23

Jan 10, 2025, 7:00 AM EST - 1 year ago

Nexalin Technology Registration statement: Registration filing

Dec 23, 2024, 10:00 AM EST - 1 year ago

Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic

Stock_Catcher Sep. 10 at 11:54 AM

$NXL thin

0 · Reply

Dante_s_Inferno Sep. 8 at 2:09 PM

$NXL is this legal? lol

0 · Reply

watchat Sep. 4 at 2:12 PM

0 · Reply

PAULSTOCK57 Sep. 4 at 1:44 PM

$NXL now we are sure we will touch 1$ ❤️

1 · Reply

Dante_s_Inferno Sep. 2 at 7:08 PM

$NXL rsi 20 lol

0 · Reply

Dante_s_Inferno Sep. 1 at 1:49 PM

$NXL drop a news f*uckin pos

0 · Reply

TwongStocks Aug. 31 at 8:18 PM

0 · Reply

TwongStocks Aug. 31 at 11:25 AM

$NXL $OMH $VBIO $VEEA $TPET are among the several stocks with reverse split today. Every stock doing a RS will resume trading at 9:00am ET this morning.

0 · Reply

PSM_EmpowerTrading Aug. 31 at 3:24 AM

0 · Reply

topstockalerts Aug. 29 at 1:51 AM

$NXL this is one of those setups you don’t want to ignore

0 · Reply

TwongStocks Aug. 28 at 8:11 PM

Tracking a total of 10 stocks with reverse splits on Monday. Nine on NASDAQ and one on the NYSE American. Expect trading to halt at 7:50pm ET tonight and resume at 9:00am Monday morning. I'll have to split the summary into two parts. Part 2 of 2: $NXL 1 for 30. Will reduce outstanding shares from approx 22.04m to approx 735k. $OMH 1 for 50. Will reduce outstanding Class A shares from approx 95.59m to approx 1.91m. $VBIO 1 for 25. Will reduce outstanding shares from approx 22.19m to approx 888k. $VEEA 1 for 20. Will reduce outstanding shares from approx 62.21m to approx 3.11m. $TPET 1 for 9. Will reduce outstanding shares from approx 44.27m to approx 4.92m.

0 · Reply

TwongStocks Aug. 27 at 6:33 PM

$NXL Equity Corporate Actions Alert #2026 - 612 Information Regarding the Reverse Stock Split and CUSIP Number Change for Nexalin Technology, Inc. (NXL) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-612 Nexalin Technology, Inc. (NXL) will effect a one-for-thirty (1-30) reverse split of its common stock. The reverse stock split will become effective on Monday, August 31, 2026. In conjunction with the reverse split, the CUSIP number will change to 65345B300.

0 · Reply

Dante_s_Inferno Aug. 27 at 12:54 PM

$NXL rs 1:30 ..scam

0 · Reply

MaskMaker Aug. 27 at 1:41 AM

$NXL

0 · Reply

MaskMaker Aug. 26 at 8:12 PM

$NXL

0 · Reply

PAULSTOCK57 Aug. 24 at 9:29 AM

$NXL 1$ this week

1 · Reply

Dante_s_Inferno Aug. 17 at 2:04 PM

$NXL management is on vacation ..pos

0 · Reply

focafoca99 Aug. 17 at 1:24 PM

$NXL awaits a Nasdaq hearing on its delisting notice scheduled for Sept. 1, 2026.

0 · Reply

MaskMaker Aug. 17 at 4:35 AM

$NXL

0 · Reply

MaskMaker Aug. 17 at 2:32 AM

$NXL

0 · Reply

MaskMaker Aug. 15 at 6:55 AM

$NXL

0 · Reply

k3vl4r Aug. 14 at 5:45 PM

Just wanted to ask, does anyone else see a bearish twist on $NXL's sales growth? I'm watching the 110.3% to 24.2% shift closely. https://app.k3vl4r.com/forecast/NXL?utm_source=x&utm_medium=social&utm_campaign=signal&utm_content=NXL #stocks #StockMarket

0 · Reply

Market Cap	3.54M
Revenue (ttm)	300,000.00
Net Income (ttm)	-8.22M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,740.00%
Debt to Equity Ratio	0.00

Volume	14,600
Avg Vol	10,431
Day's Range	N/A - N/A
Shares Out	734,000.00
Stochastic %K	10%
Beta	3.95
Analysts	Strong Sell
Price Target	$60.00